Page 35 - 83_02

compared with fluorouracil and folinic acid as
adjuvant therapy for stage III colon cancer. J Clin
Oncol. 2011;29(11):1465–71.
48. Twelves C, Scheithauer W, McKendrick J, Seitz
JF, Van Hazel G, Wong A et al. Capecitabine versus
5-fluorouracil/folinic acid as adjuvant therapy for
stage III colon cancer: final results from the X-ACT
trial with analysis by age and preliminary evidence of
a pharmacodynamic marker of efficacy. Ann
Oncol. 2012;23(5):1190-7.
49. André T, Boni C, Navarro M, Tabernero J, Hickish
T, Topham C et al. Improved overall survival with
oxaliplatin, fluorouracil, and leucovorin as adjuvant
treatment in stage II or III colon cancer in the
MOSAIC trial. J Clin Oncol. 2009;27(19):3109-16.
50. Oken MM, Creech RH, Tormey DC, Horton J, Davis
TE, McFadden ET, Carbone PP. Toxicity and
response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol. 1982;5(6):649-55.
51. Nabala M, Pascual A, Llombarth A. Valoración
general del paciente oncológico avanzado. Principios
de control de síntomas. Aten Primaria 2006;38(2):21-
8.
52. Van Cutsem E, Labianca R, Bodoky G, Barone
C, Aranda E, Nordlinger B et al. Randomized phase
III trial comparing biweekly infusional
fluorouracil/leucovorin alone or with irinotecan in the
adjuvant treatment of stage III colon cancer:
PETACC-3. J Clin Oncol. 2009;27(19):3117-25.
53. Ribecco AS, Pino MS, Cipriani G, Marinozzi C,
Fioretto L. Molecularly targeted therapy: toxicity and
quality of life considerations in advanced colorectal
cancer. Expert Rev Anticancer
Ther. 2013;13(10):1181-91.
54. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso
M, Gebbia N et al. Phase III randomized trial of
FOLFIRI versus FOLFOX4 in the treatment of
advanced colorectal cancer: a multicenter study of the
Gruppo Oncologico Dell’Italia Meridionale. J Clin
Oncol 2005; 23(22):4866-75.
55. Tournigand C, André T, Achille E, Lledo G, Flesh
M, Mery-Mignard D et al. FOLFIRI followed by
FOLFOX6 or the reverse sequence in advanced
colorectal cancer: a randomized GERCOR study. J
Clin Oncol. 2004;22(2):229-37.
56. Fichas técnicas. Agencia Española de Medicamentos y
Productos Sanitarios. Disponible en:
http://www.aemps.gob.es/cima/fichasTecnicas.do?met
odo=buscar
57. Puthillath A, Patel A, FakihMG. Targeted therapies in
the management of colorectal carcinoma: role of
bevacizumab. Onco Targets Ther. 2009;2: 1–15.
58. Qu CY, Zheng Y, Zhou M, Zhang Y, Shen F, Cao J et
al. Value of bevacizumab in treatment of colorectal
cancer: A meta-analysis. World J Gastroenterol. 2015.
28;21(16):5072-80.
198 @Real Academia Nacional de Farmacia. Spain
Ana Isabel Torres Suárez et al.
59. Qi-Bin Song, Qi Wang, Wei-Guo Hu. Anti-epidermal
growth factor receptor monoclonal antibodies in
metastatic colorectal cancer: A meta-analysis. World J
Gastroenterol. 2015. 14;21(14): 4365–72.
60. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G,
McKinnon RA, Karapetis CS. Extended RAS
mutations and anti-EGFR monoclonal antibody
survival benefit in metastatic colorectal cancer: a
meta-analysis of randomized, controlled trials. Ann
Oncol. 2015. 26(1):13-21.
61. Tejpar S, Celik I, Schlichting M, Sartorius U,
Bokemeyer C, Cutsem EV. Association of KRAS
G13D tumor mutations with outcome in patients with
metastatic colorectal cancer treated with first-line
chemotherapy with or without cetuximab. J Clin
Oncol. 2012;30(29):3570-77.
62. Van Cutsem E, Lenz HJ, Köhne CH, Heinemann
V, Tejpar S, Melezínek I et al. Fluorouracil,
leucovorin, and irinotecan plus cetuximab treatment
and RAS mutations in colorectal cancer. J Clin
Oncol. 2015;33(7):692-700.
63. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes
R, Barugel M et al. Panitumumab–FOLFOX4
Treatment and RAS Mutations in Colorectal Cancer.
N Engl J Med. 2013;369(11):1023-34.
64. Bokemeyer C, Bondarenko I, Makhson A, Hartmann
JT, Aparicio J, Braud F et al. Fluorouracil,
Leucovorin, and Oxaliplatin With and Without
Cetuximab in the First-Line Treatment of Metastatic
Colorectal Cancer. J Clin Oncol. 2009:27(5):663-71.
65. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes
R, Barugel M et al. Randomized, Phase III Trial of
Panitumumab With Infusional Fluorouracil,
Leucovorin, and Oxaliplatin (FOLFOX4) Versus
FOLFOX4 Alone As First-Line Treatment in Patients
With Previously Untreated Metastatic Colorectal
Cancer: The PRIME Study. J Clin Oncol.
2010;28(31):4697-705.
66. Van Cutsem E, Tabernero J, Lakomy R, et al.
Addition of aflibercept to fluorouracil, leucovorin, and
irinotecan improves survival in a phase III randomized
trial in patients with metastatic colorectal cancer
previously treated with an oxaliplatin-based regimen.
J Clin Oncol. 2012;30(28): 3499–3506.
67. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H et al.
Regorafenib plus best supportive care versus placebo
plus best supportive care in Asian patients with
previously treated metastatic colorectal cancer
(CONCUR): a randomised, double-blind, placebo-
controlled, phase 3 trial. Lancet Oncol.
2015;16(6):619-29.
68. Abstract number 0-0022. 16th ESMO World Congress
on Gastrointestinal Cancer. Phase III Trial Shows
Improved Survival With TAS-102 in Metastatic
Colorectal Cancer Refractory to Standard Therapies.
Ann Oncol. 2014;25(2).